PharmaMar Aims For A Second Marketed Product With EU Aplidin Filing
Executive Summary
Spanish company PharmaMar has filed for approval of its anticancer Aplidin in the EU, which if successful would be its second product to reach the market.
You may also be interested in...
PharmaMar Endures Second Recent Setback With Phase III Ovarian Cancer Failure
Zepsyre did not show a PFS advantage measured against a comparator regimen in platinum-resistant ovarian cancer, but the novel chemotherapy is being tested in nine other cancers.
Deal Watch: Takeda Seeks A Crescendo With Collaboration On New Type Of Cancer Compound
AstraZeneca concludes week of four out-licensing transactions by selling US rights to Toprol XL to Aralez and ex-US rights to Rhinocort Aqua to J&J. Molecular Partners gets back rights to an IL-13/IL-17 inhibitor for pulmonary indications after a 2011 deal with Janssen unravels.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.